Effects of BPA in Snails

metabolize diazoxon and chlorpyrifos oxon than their mothers (Furlong et al. 2006). To further support the concern for children indicated by our quantitative risk assessment, we cited toxicologic studies establishing that in addition to chloinesterase inhibition, on which the NOAEL for chlorpyrifos is established, chlorpyrifos and chlorpyrifos oxon have other neurodevelopmental toxicity mechanisms (Huff et al. 1994; Qiao et al. 2002). We also noted that cell death has been induced at the reference dose for drinking water (Greenlee et al. 2005). Peterson argues that the toxicologic studies we cited (Castorina and Woodruff, 2003; Eskenazi et al. 1999; Faustmann et al. 2000; Greenlee et al. 2005; Huff et al. 1994; Qiao et al. 2002) are an insufficient review of the “literature relevant to risk assessment” and that these studies are not appropriate for use in risk assessment. However, in missing the fact that we conducted a quantitative risk assessment, Peterson is misinterpreting our citations as the only basis for our public health concern. We consider it our public health responsibility to at least qualitatively consider recent toxicologic data in addition to a quantitative risk assessment based on established reference values. Others have argued for a complete restructuring of risk assessment for children, including toxicokinetic modeling and assessment of cellular and molecular outcomes over the entire lifespan of experimental subjects (Landrigan et al. 2004). For many reasons we disagree with the suggestion that the epidemiologic fetal growth and gestational duration findings of Eskenazi et al. (2004) may be used to disregard concern for in utero and child organophosphate exposure highlighted by Eskenazi et al. (1999). The associations of reduced gestational duration with dimethyl organophosphate urinary metabolites and chloinesterase inhibition were not clinically significant in the California population studied (recent Mexican immigrants who tend to have very healthy birth outcomes). However, a shortened gestational age of a half-week would represent, for some women, a risk of preterm delivery (Eskenazi et al. 2004). Clearly, this finding and the absence of any adverse association between fetal growth and measures of in utero pesticide exposure need to be confirmed or refuted. To be complete, however, we also cited the association found in a New York City population between low birth weight and length and cord plasma levels of chlorpyrifos and diazinon (n = 314) (Whyatt et al. 2004). Further, effects of organophosphate pesticide exposure on early child neurodevelopment have been found (Young et al. 2005) and are continuing to be evaluated in the California and the New York City cohorts. Finally, public health policy is typically developed to protect against a 1 in 1,000, or lower, risk, and the epidemiologic studies cited here are below the sample size necessary to detect such risks. Peterson notes that a study of children in 10 homes did not demonstrate an association with child urine metabolite levels of chlorpyrifos and ambient air levels following crack and crevice treatment (Hore et al. 2005). Yet, the authors of that study were careful to note a number of study limitations, including the variability and accuracy of the child urinary metabolite readings. We also note that chloryprifos oxon, which also breaks down into the measured urinary metabolite, was not measured in air; air concentrations in four of the study homes were not elevated compared to pretreatment levels; and personal air samples were not collected (Hore et al. 2005). Among mothers in New York City (n = 314) in another study, 48-hr personal air samples collected during pregnancy were associated with cord and maternal blood levels of chlorpyrifos (Whyatt et al. 2004). This is the same study population within which an association with adverse birth outcomes and pesticide cord blood levels has been demonstrated, and the chlorpyrifos air levels are in the same (average, 15 ng/m3) range, if not lower, as those evaluated in our health risk assessment (Whyatt et al. 2004). The authors declare they have no competing financial interests